Propranolol in Portal Hypertension: Problems in Paradise?
Authors: Harold O. Conn
Journal: Hepatology (1984)

HepatologyVolume 4, Issue 3 p. 560-564 EditorialsFree Access Propranolol in Portal Hypertension: Problems in Paradise? Harold O. Conn, Corresponding Author Harold O. Conn Harold O. Conn, M.D., Veterans Administration Medical Center, West Spring Street, West Haven, Connecticut 06516.Veterans Administration Medical Center West Haven, Connecticut 06516 and The Yale University School of Medicine New Haven, Connecticut 06510===Search for more papers by this author Harold O. Conn, Corresponding Author Harold O. Conn Harold O. Conn, M.D., Veterans Administration Medical Center, West Spring Street, West Haven, Connecticut 06516.Veterans Administration Medical Center West Haven, Connecticut 06516 and The Yale University School of Medicine New Haven, Connecticut 06510===Search for more papers by this author First published: May‐June 1984 https://doi.org/10.1002/hep.1840040333Citations: 22AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Lebrec D, Nouel O, Corbie M, et al. Propranolol–A medical treatment for portal hypertension? Lancet 1980; 2: 180– 182. 2 Lebrec D, Nouel O, Bernuau J, et al. Propranolol in prevention of recurrent gastrointestinal bleeding in cirrhotic patients. Lancet 1981; 1: 920– 921. 3 Lebrec D, Poynard T, Hillon P, et al. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis. A controlled study. N Engl J Med 1981; 305: 1371– 1374. 4 Lebrec D, Poynard T, Bercoff E, et al. A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology 1984; 4: 355– 358. 5 Conn HO. Propranolol in the treatment of portal hypertension: a caution. Hepatology 1982; 2: 641– 644. 6 Burroughs AK, Jenkins WJ, Sherlock S, et al. Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. N Engl J Med 1983; 309: 1539– 1542. 7 Resnick RH, Iber FL, Ishihara AM. A controlled study of the therapeutic portacaval shunt. Gastroenterology 1974; 67: 843– 857. 8 Jackson FC, Perrin EB, Felix R, et al. A clinical investigation of the portacaval shunt: V. Survival analysis of the therapeutic operation. Ann Surg 1971; 174: 672– 701. 9 Rueff B, Degos F, Degos JD, et al. A controlled study of therapeutic portacaval shunt in alcoholic cirrhosis. Lancet 1976; 1: 655– 659. 10 Reynolds TB, Donovan AJ, Mikkelsen WP, et al. Results of a 12 year randomized trial of portacaval shunt in patients with alcoholic liver disease and bleeding varices. Gastroenterology 1981; 80: 1005– 1011. 11 Rikkers LF, Rudman D, Galambos JT, et al. A randomized, controlled trial of the distal splenorenal shunt. Ann Surg 1978; 188: 271– 282. 12 Conn HO, Resnick RH, Grace ND, et al. Distal splenorenal shunt vs. portal-systemic shunt: current status of a controlled trial. Hepatology 1981; 1: 151– 160. 13 Langer B, Taylor BR, Mackenzie DR, et al. Further report of a prospective randomized trial comparing distal splenorenal shunt to end-to-side portacaval shunt: an analysis of encephalopathy, survival, and quality of life. Gastroenterology 1984 (in press). 14 Conn HO. A peek at the Child-Turcotte classification. Hepatology 1981; 1: 673– 676. 15 Brantigan CO, Brantigan TA, Joseph N. Effect of beta blockade and beta stimulation on stage fright. Am J Med 1982; 72: 88– 94. 16 Copenhagen Study Group for Liver Diseases. Sexascites, and alcoholism in survival of patients with cirrhosis: effect of prednisone. N Engl J Med 1974; 291: 271– 273. 17 Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1– 39. 18 VanBuuren HR, Koorevaar G, van der Velden PC. Propranolol increases arterial ammonia in liver cirrhosis. Lancet 1982; 2: 951– 952. 19 Conn HO. Trailmaking and NCT in the assessment of mental state in portal-systemic encephalopathy. Dig Dis 1977; 22: 541– 550. 20 Tarver D, Walt RP, Dunk AA, et al. Precipitation of hepatic encephalopathy by propranolol in cirrhosis. Br Med J 1983; 287: 585. 21 Hillon P, Lebrec D, Munoz C, et al. Comparison of the effects of a cardioselective and a nonselective /i-blockade on portal hypertension in patients with cirrhosis. Hepatology 1982; 2: 528– 531. 22 Butzow GH, Remmecke J, Brauer A. Metoprolol in portal hypertension. A controlled study. Klin Wochenschr 1982; 60: 1311– 1314. 23 Lebrec D, Hillon P, Munoz C, et al. The effect of propranolol on portal hypertension in patients with cirrhosis: a hemodynamic study. Hepatology 1982; 2: 523– 527. 24 Lebrec D, DeFleury P, Rueff B, et al. Portal hypertension, size of esophageal varices, and risk of gastrointestinal bleeding in alcoholic cirrhosis. Gastroenterology 1980; 79: 1139– 1144. 25 Conn HO. The varix-volcano connection. Gastroenterology 1980; 79: 1333– 1337. 26 Mitchell KJ, Macdougall BRD, Silk DBA, et al. A prospective reappraisal of emergency endoscopy in patients with portal hypertension. Scand J Gastroenterol 1982; 17: 965– 968. 27 Smith JL, Graham DY. Variceal hemorrhage: a critical evaluation of survival analysis. Gastroenterology 1982; 82: 968– 973. Citing Literature Volume4, Issue3May‐June 1984Pages 560-564 ReferencesRelatedInformation